BW
NKGN

Boaz Weinstein’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Boaz Weinstein’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-415,330
Closed -$4.05M – 958
2022
Q3 		$4.05M Hold
415,330
– – 0.05% 559
2022
Q2 		$4.03M Hold
415,330
– – 0.05% 563
2022
Q1 		$4.03M Hold
415,330
– – 0.06% 475
2021
Q4 		$4.02M Buy
415,330
+150,200
+57% +$1.46M 0.06% 409
2021
Q3 		$2.57M Buy
+265,130
New +$2.59M 0.06% 331

Other funds holding NKGN

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
CIM
Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

Boaz Weinstein's NKGN Position: Q4 2022 in Review

Boaz Weinstein sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q4 2022, closing a stake of 415,330 shares — an estimated $4.05M sold.

Boaz Weinstein first reported a position in NKGN in Q3 2021 and held it in 5 quarters. The position peaked at $4.05M in Q3 2022. 59 funds tracked by Wall St. Rank hold NKGN as of Q4 2022.

  • Boaz Weinstein reported no remaining NKGen Biotech, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Boaz Weinstein sold 415,330 NKGen Biotech, Inc. Common Stock shares in Q4 2022, an estimated $4.05M.
  • Boaz Weinstein first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 5 quarters.
  • Boaz Weinstein's NKGen Biotech, Inc. Common Stock position peaked at $4.05M in Q3 2022.
  • 59 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q4 2022.

Based on Saba Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.